# OPKO Health, Inc.

Organization · id `cardio:org-opko-health-inc` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=OPKO+Health%2C+Inc.>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: OPKO Health, Inc.
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes (`cardio:ct-nct02119819`)
- Sponsors: Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 (`cardio:ct-nct02282813`)
- Sponsors: Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects (`cardio:ct-nct03406377`)

## Provenance

Content hash: 20ca3e7b177593dd9d20edfb0c3f25aca9e15b20ee5ed6a2c08f9fb631757b8d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
